Ultraconserved Regions Encoding ncRNAs
AssigneeThe Ohio State University
InventorCarlo M. Croce
Life of this patent
Estimating the term…
Abstract
Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs.
Claims21
A method of diagnosing whether a subject has, or is at risk for developing, a cancer linked to a cancer-associated chromosomal feature, comprising evaluating the status in the subject of at least one UCR gene located in close proximity to the cancer-associated chromosomal feature, by analyzing the at least one UCR gene in the test sample for a deletion, mutation or amplification, wherein detection of a deletion, mutation and/or amplification in the UCR gene as compared to the corresponding UCR gene in the control sample is indicative of the subject either having, or being at risk for developing, the cancer.
A method to identify a relative risk in a vertebrate for developing a cancer, comprising:
- (a) obtaining a nucleic acid-containing test sample from a vertebrate subject,
- (b) measuring, by laboratory analysis, a level of at least one transcribed ultra-conserved regions (T-UCR),
- (c) identifying whether the test sample expresses at least one T-UCR,
- (d) determining the relative risk for developing the cancer by comparing the at least one T-UCR measured level to the level of a corresponding T-UCR in a control sample,
- wherein an alteration in the level of at least one T-UCR in the test sample, relative to the level of a corresponding T-UCR in a control sample, is indicative of the subject either having, or being at risk for developing the cancer.
A method of diagnosing whether a subject has, or is at risk for developing, a cancer, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising one or more UCR specific probe oligonucleotides to provide a hybridization profile for the test sample;
- and (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample, and (4) diagnosing the subject as having or at risk for developing cancer if the test sample shows an alteration in the signal as compared to the control.
A method of treating cancer in a subject, comprising:
- (1) providing a subject who has a cancer associated with a cancer-associated chromosomal feature, in which at least one isolated UCR gene product from a UCR gene located in close proximity to the cancer-associated chromosomal feature is down-regulated or up-regulated in cancer cells of the subject as compared to control cells;
- and
- (2) (a) when the at least one isolated UCR gene product is down-regulated in the cancer cells, administering to the subject an effective amount of at least one isolated UCR gene product from the at least one UCR gene, such that proliferation of cancer cells in the subject is inhibited;
- or (b) when the at least one isolated UCR gene product is up-regulated in the cancer cells, administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one UCR gene, such that proliferation of cancer cells in the subject is inhibited.
A cDNA that is complementary to a T-UCR selected from the group consisting essentially of:
- uc.347;
- uc.348;
- uc.349;
- uc.350;
- uc.351;
- uc352;
- uc.353;
- uc.269A(N), uc.160(N), uc.215(N), uc.346A(P);
- uc.348(N);
- and uc.73(P).
A pharmaceutical composition comprising a UCR gene product or complement and a pharmaceutically-acceptable carrier, wherein the isolated UCR gene product or complement is from a UCR gene located in close proximity to a cancer-associated chromosomal feature.
A pharmaceutical composition for treating a cancer, comprising
- at least one UCR expression-inhibition compound, and
- a pharmaceutically-acceptable carrier,
- wherein the at least one UCR expression-inhibition compound is specific for a UCR gene product selected from the group consisting of:
- a cluster of seven UCRs of uc.347 through uc.353, and combinations thereof.
A computer-assisted method for evaluating the presence, absence, nature or extent of a cancer-related disease in a subject, comprising:
- (1) providing a computer comprising a model or algorithm for classifying data from a sample obtained from the subject,
- wherein the classification includes analyzing the data for the presence, absence or amount of at least one marker, and
- wherein the marker comprises one or more UCR genes or gene products, provided that the UCR gene or gene product has been shown to be statistically significant in such association with cancer-related disease;
- (2) inputting data from the biological sample obtained from the subject;
- and,
- (3) classifying the biological sample to indicate the presence, absence, nature or extent of a cancer-related disease.
Dependencies are inferred from the claim text.